Despite a string of downgrades and adjustments in Ambu’s past three consecutive quarters, as well as circulating rumors that CEO Juan Jose Gonzalez’s seat is getting hotter, the man himself rejects the notion that his position is in jeopardy.
In May 2019, Gonzalez stepped into Ambu’s headquarters in the Danish town of Ballerup for the first time. Since then, he has been the company’s figurehead as six downgrades and adjustments have come and gone – the latest of which occurred today, in connection with Tuesday’s quarterly report. Share price growth, which despite some fluctuations has been on a steady decline of 12 percent since he was appointed, has been conspicuously absent.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.